BR112013003682A2 - methods to treat neurodegenerative diseases - Google Patents

methods to treat neurodegenerative diseases

Info

Publication number
BR112013003682A2
BR112013003682A2 BR112013003682A BR112013003682A BR112013003682A2 BR 112013003682 A2 BR112013003682 A2 BR 112013003682A2 BR 112013003682 A BR112013003682 A BR 112013003682A BR 112013003682 A BR112013003682 A BR 112013003682A BR 112013003682 A2 BR112013003682 A2 BR 112013003682A2
Authority
BR
Brazil
Prior art keywords
isomers
methods
neurodegenerative diseases
geranylgeranyl acetone
increasing
Prior art date
Application number
BR112013003682A
Other languages
Portuguese (pt)
Inventor
Ankush B Argade
Ben A Barres
Hiroaki Serizawa
Naoki Nakayama
Original Assignee
Coyote Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coyote Pharmaceuticals Inc filed Critical Coyote Pharmaceuticals Inc
Publication of BR112013003682A2 publication Critical patent/BR112013003682A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/203—Unsaturated compounds containing keto groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/147—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/15—Unsaturated ethers containing only non-aromatic carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/303—Compounds having groups having acetal carbon atoms bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C07C45/676—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton by elimination of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

métodos para tratar doenças neurodegenerativas. a presente invenção refere-se aos isômeros 5-cis e 5-trans de geranilgeranil acetona, prefencialmente os isômeros sintéticos referidos, e composições farmacêuticas contendo os isômeros referidos. outros aspectos desta invenção se referem ao uso de geranilgeranil acetona e seus isômeros em métodos para inibição de morte neural, para aumentar a atividade neural, e para aumentar o crescimento de axônios e a viabilidade celular. geranilgeranil acetona é um fármaco antiúlcera conhecido usado comercialmente e em situações clínicas. além disso, foi demonstrado que a gga exerce efeitos citoprotetores sobre uma variedade de órgãos, tais como os olhos, o cérebro, eo coração.methods for treating neurodegenerative diseases. The present invention relates to 5-cis and 5-trans isomers of geranylgeranyl acetone, preferably said synthetic isomers, and pharmaceutical compositions containing said isomers. Other aspects of this invention relate to the use of geranylgeranyl acetone and its isomers in methods for inhibiting neural death, increasing neural activity, and increasing axon growth and cell viability. Geranylgeranyl acetone is a known antiulcer drug used commercially and in clinical situations. In addition, gga has been shown to exert cytoprotective effects on a variety of organs, such as the eyes, brain, and heart.

BR112013003682A 2010-09-01 2011-08-31 methods to treat neurodegenerative diseases BR112013003682A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37931610P 2010-09-01 2010-09-01
US201161510002P 2011-07-20 2011-07-20
PCT/US2011/050071 WO2012031028A2 (en) 2010-09-01 2011-08-31 Methods for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
BR112013003682A2 true BR112013003682A2 (en) 2016-09-06

Family

ID=45773508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003682A BR112013003682A2 (en) 2010-09-01 2011-08-31 methods to treat neurodegenerative diseases

Country Status (11)

Country Link
US (1) US20120172453A1 (en)
EP (1) EP2611765A4 (en)
JP (1) JP2013540720A (en)
KR (1) KR20130109103A (en)
CN (1) CN103052619A (en)
AU (1) AU2011295920A1 (en)
BR (1) BR112013003682A2 (en)
CA (1) CA2806238A1 (en)
MX (1) MX2013001236A (en)
RU (1) RU2013104184A (en)
WO (1) WO2012031028A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530810A (en) * 2011-10-04 2014-11-20 コヨーテ ファーマシューティカルズ インコーポレイテッド Geranylgeranylacetone derivatives
WO2013129315A1 (en) * 2012-02-27 2013-09-06 ロート製薬株式会社 Prophylactic, ameliorating or therapeutic agent for retinal diseases
WO2013129317A1 (en) * 2012-02-27 2013-09-06 ロート製薬株式会社 Ophthalmic composition containing geranylgeranylacetone
WO2013130242A1 (en) * 2012-02-29 2013-09-06 Coyote Pharmaceuticals, Inc. Geranylgeranylacetone formulations
US20150025077A1 (en) 2012-02-29 2015-01-22 Coyote Pharmaceuticals, Inc. Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof
WO2014107686A1 (en) * 2013-01-07 2014-07-10 Coyote Pharmaceuticals, Inc. Methods for treating neuron damage
WO2014123977A1 (en) * 2013-02-06 2014-08-14 Rohto Usa, Inc. Geranylgeranylacetone formulations
WO2014151697A1 (en) * 2013-03-15 2014-09-25 Coyote Pharmaceuticals, Inc. Therapeutic uses for geranylgeranyl acetone and derivatives thereof
WO2014151719A1 (en) * 2013-03-15 2014-09-25 Coyote Pharmaceuticals, Inc. Sublingual formulations including geranylgeranylacetone and geranylgeranylacetone derivatives
WO2014163643A1 (en) * 2013-04-04 2014-10-09 Coyote Pharmaceuticals, Inc. Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
US20150133431A1 (en) * 2013-07-11 2015-05-14 Coyote Pharmaceuticals, Inc. Gga derivatives
JPWO2015029925A1 (en) * 2013-08-26 2017-03-02 ロート製薬株式会社 Retinal disease prevention, amelioration, or treatment
WO2015038680A1 (en) * 2013-09-11 2015-03-19 Coyote Pharmaceuticals, Inc. Drug conjugates of gga and gga derivatives
CN104447256A (en) * 2014-11-13 2015-03-25 岳阳新华达制药有限公司 Preparation method for intermediate (5E, 9E)-farnesyl acetone of teprenone
WO2016085954A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Geranygeranylacetone and analogs thereof and phenoxyalkylcarboxlic acids for treating fibrosis
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
CA3104291A1 (en) 2018-06-21 2019-12-26 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
CN114031491B (en) * 2021-11-26 2023-10-24 安徽先和医药研究有限公司 Preparation method of all-trans-teprenone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192073A (en) * 1992-12-24 1994-07-12 Eisai Co Ltd Cell differentiation-inducing agent
EP1001987B1 (en) * 1997-08-01 2010-12-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
JP4632480B2 (en) * 2000-05-16 2011-02-16 レドックス・バイオサイエンス株式会社 Thioredoxin inducer
US20040249219A1 (en) * 2000-07-05 2004-12-09 Saucy Gabriel G. Method of making teprenone
US20060135623A1 (en) * 2004-05-21 2006-06-22 Cutler Richard G Decrease in oxidative stress status through the administration of natural products and pharmaceutical drugs
WO2010042841A1 (en) * 2008-10-09 2010-04-15 University Of North Texas Health Science Center Combination therapies for the treatment of degenerative inflammatory conditions of the nervous system

Also Published As

Publication number Publication date
AU2011295920A1 (en) 2013-01-24
RU2013104184A (en) 2014-10-10
WO2012031028A3 (en) 2012-07-05
EP2611765A2 (en) 2013-07-10
EP2611765A4 (en) 2014-06-11
MX2013001236A (en) 2013-05-01
JP2013540720A (en) 2013-11-07
CN103052619A (en) 2013-04-17
US20120172453A1 (en) 2012-07-05
KR20130109103A (en) 2013-10-07
CA2806238A1 (en) 2012-03-08
WO2012031028A2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
BR112013003682A2 (en) methods to treat neurodegenerative diseases
CO2017011851A2 (en) Novel compounds
CU20120099A7 (en) DERIVATIVES OF PIRAZINA AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
BR112019022512A2 (en) 6-6 Fused BICYCLICAL HETEROARYL COMPOUNDS AND THEIR USE AS LATH INHIBITORS
BR112015011158A2 (en) triazolopyrazine
BR112014021634A8 (en) serine / threonine kinase inhibitors, compositions comprising them, their uses and their preparation processes, and method of inhibiting erk protein kinase activity in a cell
BR112013020041A2 (en) compounds and methods for modulating kinases, and indications thereof
BR112012021364A2 (en) "thienopyrimidines-containing cycloalkyl compounds and pharmaceutical compositions".
BR112015023948A2 (en) compound of formula (i), pharmaceutical composition, method for treating and / or preventing a proliferative disease and for inhibiting or differentiating growth of a cancer stem cell
BR112015028879A8 (en) heterocyclic derivative compounds, pharmaceutical composition comprising said compounds and uses thereof
PE20151375A1 (en) CYCLIC COMPOUNDS ETER PIRAZOL-4-IL-HETEROCICLIL-CARBOXAMIDE AND METHODS OF USE
BR112014027571A2 (en) Methods for the treatment of diabetic retinopathy and other eye diseases
BR112015011298A2 (en) sodium glucose cotransporter 1 inhibitors
BR112013018920A2 (en) nanoparticle compositions, formulations thereof and their uses
BR112013000107A2 (en) aminopyrazoloquinazolines
UY32582A (en) 3 KINASE PHOSPHINOSITI INHIBITORS AND / OR MAMMAL OBJECTIVE
BR112015023412A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant idh inhibitors, their pharmaceutical composition and their use.
GT201400064A (en) DERIVATIVES OF 8-CARBAMOIL-2- (2,3- PIRID-6-ILO DI REPLACED) -1,2,3,4- TETRAHYDROISOQUINOLINE AS INDUCTIVE AGENTS OF APOPTOSIS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOINMUNE DISEASES
BR112012023421A2 (en) pharmaceutical composition for intraocular pressure increase treatment
CU20120013A7 (en) OXACINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CO7310531A2 (en) 4-methyl-2,3,8,9,9b-pentaaza-cyclopenta [a] naphthalenes
BR112015003729A2 (en) compound of formula I; pharmaceutical composition; method of treating a hyphenated pathway disease; method of treating a disease caused by abnormal cell proliferation; and method to achieve an effect on a patient
UY35827A (en) TRIAZOLOPIRAZINE DERIVATIVES AS INHIBITORS OF THE BRD4 PROTEIN
BR112012006010A2 (en) glycine compound
BR112014018421A8 (en) ANTIMICROBIAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA AND/OR 15-HETRE AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]